Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Ines Vaz Luis, MD, MSc


No Ratings Available - Why Not?

Ines Vaz Luis, MD, MSc

Researcher

Clinical Interests

  • Patterns of care and outcomes of breast cancer patients.

Contact Information

  • Office Phone Number617-632-3732

Bio

I am a medical oncologist focused on the care of women with breast cancer. My primary research is centered on the patterns of care and outcomes for breast cancer patients. I graduated with a medical degree in 2003 from the University of Lisbon and I completed my fellowship in medical oncology at the Hospital de Santa Maria, in Lisbon, in 2011.  At this point I was awarded with a training grant from the Fundacao Ciencia e Tecnologia as part of a joint program between Portugal and Harvard Medical School. I joined the Breast Oncology Center (BOC) at the Dana-Farber Cancer Institute (DFCI) and I was enrolled in the Scholars of Clinical Science Program (SCSP). The SCSP provided me with formal skills in fields such as epidemiology, biostatistics, clinical trials, commercialization of science, and applied genetics. At the same time, under outstanding mentorship I was able to apply those skill sets to a different range of mentored projects that included outcomes research, clinical trials, and translational research. More specifically, I completed studies on patterns of care and outcomes among the National Comprehensive Network (NCCN) in HER2-positive disease and small node negative disease; I also participated in several analyses of utilization adjuvant trastuzumab within Surveillance, Epidemiology and End Results (SEER)-Medicare and we are completing analyses looking to patterns of care and outcomes for patients with MBC treated with trastuzumab. In addition, I examined outcomes among patients with HER2-positive breast cancer within the DFCI cancer database and I was able to identify patients of particular translational interest (patients with extreme and prolonged responses to trastuzumab therapy). I also participated in several PI-initiated trials which are currently enrolling patients. In February, 01, 2014 I became an Instructor of Medicine at Harvard Medical School. My primary academic goal is to develop into an independent, patient-oriented clinical researcher

 

Research

 

{line break}

Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Breast Cancer Res 2012, 14(5): R129. PMID: 23025714

{line break}

 

2012

Casimiro S, Vaz-Luis I, Fernandes A, Pires R, Pinto A, Gouveia AG, Francisco AF, Portela J, Correia L, Costa L:  Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clin Exp Metastasis. 2012, 29(2):155-64. PMID:22120474

2012

 Vaz-Luis I, Seah D, Olson E, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU: Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first line trastuzumab based therapy: A retrospective cohort study. Clinical Breast Cancer 2013, 13 (4): 254-63. PMID: 23829891

2013

Vaz-Luis I, Zeghibe CA, Frank E, Sohl J, Washington K, Silverman S, Erica L. Mayer EL, Overmoyer B , Richardson A, Krop I, Winer EP, Lin NU. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Research and Treatment 2013, 42(1):203-9. PMID: 24113744

{line break}

 

2013

Seah DS, Vaz-Luis I, Olson E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. JNCCN 2014, 12(1):71-80. PMID: 24453294

{line break}

 

2014

Vaz-Luis I, Winer E, Lin NU: Human epidermal growth factor receptor-2 positive Breast Cancer:  Does Estrogen Receptor status define two distinct subtypes? Annals of Oncology 2013, 24 (2). PMID: 23022997

2012

 Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RF. Duration and toxicity of adjuvant trastuzumab in older patients with early-breast cancer: A population-based study.  Journal of Clinical Oncology, 2014, published online ahead of print.PMID:24516021

2014

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault R, Weeks J, Winer EP, Lin N. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study, Journal of Clinical Oncology, 2014, accepted for publication.

2014

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Yawkey 1242
Boston, MA 02215
Get Directions

Top